← ABEONA THERAPEUTICS INC. (ABEO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ABEONA THERAPEUTICS INC. (ABEO)
Pharmaceutical Preparations · market cap $325M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Abeona Therapeutics (ABEO) is a small-cap pharmaceutical company with 136 employees and a ~$373M market cap focused primarily on rare skin diseases and wound care. Its most advanced asset is EB-101, a gene-therapy-based autologous epidermal sheet product in Phase 3 for recessive dystrophic epidermolysis bullosa (RDEB), alongside MSI-78 and ofloxacin in Phase 3 for diabetic foot ulcers. With $61.4M cash and a ~9.3-month runway, the company faces near-term financing pressure.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ofloxacin | Phase 3 | Diabetic Foot Ulcers |
| EB-101 | Phase 3 | Epidermolysis Bullosa |
| EB-101 Surgical application of RDEB wounds | Phase 3 | Epidermolysis Bullosa |
| MSI-78 | Phase 3 | Diabetic Foot Ulcers |
| EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) | Phase 2 | Onychomycosis |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Phase 2 | Epidermolysis Bullosa Dystrophica |
Price & technical context
3-month
-21.7%
6-month
+9.4%
12-month
-5.1%
52-wk range
$4.17–$7.46
vs 50-day MA
-16.8%
vs 200-day MA
-9.7%
Realized vol
52.9%
Max drawdown
-42.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABEO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.